中国中药(00570.HK)上半年经调整EBITDA升13.3%至15.22亿元中期息5.72港仙
格隆汇8月19日丨中国中药(00570.HK)发布中期业绩,截至2019年6月30日止6个月,公司实现营业额69.37亿元人民币(下同),同比增长27.0%;毛利41.87亿元,同比增长42.9%;公司股权持有人应占溢利8.59亿元,同比增长13.0%;经调整EBITDA15.22亿元,同比增长13.3%;基本每股收益17.06分;拟派中期股息每股5.72港仙。
报告期内,中药配方颗粒业务销售增长迅速,营业额约45.71亿元,较上年同期增长31.1%,占总营业额的65.9%。销售收入快速增长主要得益于:(1)配方颗粒的质量可控性及便利性等优势明显,以及卓有成效的学术推广,市场认可度逐步提高,存量客户带来的销售增长约18.2%;(2)顺应市场和医改政策,公司近年不断加大对新客户的开发力度,以进一步加大市场占有率,本期新增客户带来的销售增长约12.9%。
公告表示,今年是集团实施“全面打造行业领先的中药大健康产业集团”这一五年战略的第二年,各项业务根据规划稳步推进。据权威统计,集团位列国家药品监督管理局南方医药经济研究所评选的“2018年度中国医药工业百强系列-中国中药企业”第五位。集团在中药行业的影响力稳步提升,形成长远发展格局更加清晰、基础更加夯实、平台更加广阔的良好局面。
与过去强调快速外延扩张的阶段相比,今年以来,公司进入了为保持长久可持续发展强本固基的阶段,战略部署以优化管控模式为首要重点,着重推进创新管理、提质增效工作,确保集团在生产经营过程中行稳致远。集团充分把握国家医药行业政策调整的机遇,紧跟行业发展的新趋势,在增量业务培育升级期间,稳步提升存量业务,集团整体收入、利润得到进一步提升。
下半年,集团工作重点为以下五点:一是紧抓药材品质,深度管控大品种中药材基地,做到做一个品种,对一个品种掌握真实控制力和话语权;二是在协同四大板块业务稳步增长的前提下,继续推动“产地综合业务”落地,完善全国产业布局规划,尽快实现相关的中药饮片业务正式投产;三是在前期研究工作基础上,继续开展配方颗粒国家标准研究、经典名方研究,并在研究过程中加强新技术的应用,不断提高工艺和质量控制水平,同时加强专利保护,设立技术门槛,在行业内继续保持技术领先;四是隆重推出龙印“中国药材”品牌,全力建立集团产品“原料来自药材主产区的优质中药”的认知体系,对各业务板块实行精准化、差异化市场营销策略;五是集团将利用现有中药材和中药饮片的优势品种,遵循古法炮制融合现代工艺,突出道地属性和质量安全性的特点,以最优的等级规格、可追溯的质量保障,推出精品高端饮片系列,打开并逐步扩张高端中药饮片消费市场。
与此同时,集团会继续密切关注国家行业政策变化,注意收集国家及各省医药行业政策信息,并与公司各大业务板块重点项目的进展、市场数据有机结合起来,分析政策影响和政策趋势,适应国家要求做好转型升级,实现集约化、规范化发展,完善制度建设,将暂时的政策“压力”转变为长远的政策“红利”,在新的医药格局下始终立于不败之地。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.